@article{92a96e711f9b493c97aee51812610a71,
title = "Colistin versus colistin plus meropenem for severe infections Authors' reply",
author = "Mical Paul and Yehuda Carmeli and Daikos, {George L.} and Emanuele Durante-Mangoni and Ursula Theuretzbacher and Mouton, {Johan W.} and Leonard Leibovici",
note = "Funding Information: GLD has received research funding from Pfizer, Achaogen, Rempex, MSD, and Gilead, outside the submitted work. ED-M has received research funding from MSD, Pfizer, BioM{\'e}rieux, Abbvie, Sanofi-Aventis, Medtronic, and DiaSorin, outside the submitted work. YC has received research funding from MSD, AstraZeneca, Allecra Therapeutics, DaVoltera, Intercell AG, BioM{\'e}rieux SA, Rempex Pharmaceuticals, Nariva, Achoagen, Roche, Pfizer, and Shionogi, outside the submitted work. JWM has received research funding from Adenium, AstraZeneca, Basilea, Cubist, Polyphor, Roche, Eumedica, Basilea, VenatorX, AiCuris, Gilead, and Wockhardt, outside the submitted work. MP, UT, and LL declare no competing interests.",
year = "2018",
month = may,
doi = "10.1016/S1473-3099(18)30223-8",
language = "אנגלית",
volume = "18",
pages = "495--496",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "5",
}
